95
Participants
Start Date
April 10, 2023
Primary Completion Date
March 19, 2025
Study Completion Date
July 15, 2025
Anti-BK polyomavirus (AntiBKV)
"Participants in the study arm will each receive four doses (1,000 mg; 1,000 mg or 500 mg in the dose comparison part) of IMP administered at four-week intervals.~IMP will be administered on Days 1, 29, 57 and 85."
New York Presbyterian Hospital - Weill Cornell Medical Center, New York
University of Pennsylvania Hospital of Pennsylvania, Philadelphia
MedStar Georgetown University Hospital, Washington D.C.
University of Maryland, Baltimore
Metrolina Nephrology Associates (MNA), PA, Charlotte
Mayo Clinic Transplant Center, Jacksonville
University of Alabama at Birmingham, Birmingham
Ohio State University, Columbus
Cleveland Clinic, Cleveland
University of Michigan Health System, Ann Arbor
Washington University School of Medicine in St. Louis, St Louis
University of Kansas Medical Center, Kansas City
UT Southwestern, Dallas
Mayo Clinic, Phoenix
University of California, Los Angeles, Los Angeles
Cedars-Sinai Medical Center, Los Angeles
University of California Davis, Sacramento
University of Washington Medical Center, Seattle
Hartford Hospital, Hartford
Yale University School of Medicine, New Haven
Massachusetts General Hospital, Boston
Harvard Medical School, Boston
Saint Barnabas Medical Center, Livingston
Lead Sponsor
Memo Therapeutics AG
INDUSTRY